AGN,Valeant says sweetened bid for Allergan will not be all-cashCANADA STOCKS-Resource shares, Valeant nudge TSX higherUPDATE 3-Valeant says improved bid for Allergan won't be all-cashValeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.  Valeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker. LAVAL, QUEBEC, May 20 Canada's Valeant Pharmaceuticals International said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.Valeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.   UPDATE 3-Valeant says improved bid for Allergan won't be all-cashValeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.  Valeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker. LAVAL, QUEBEC, May 20 Canada's Valeant Pharmaceuticals International said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.Valeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.  * TSX rises 25.67 points, or 0.18 percent, to 14,540.41     * Seven of the 10 main index sectors advance     * Valeant higher after commenting on Allergan bid plans      By John Tilak     TORONTO, May 20 Canada's main stock index climbed slightly on Tuesday as gains in materials and energy shares helped offset weakness in the financial sector.     Providing further support was a rise in shares of Valeant Pharmaceuticals International Inc after the drugmaker said its sweetened takeoveUPDATE 3-Valeant says improved bid for Allergan won't be all-cashValeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.  Valeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker. LAVAL, QUEBEC, May 20 Canada's Valeant Pharmaceuticals International said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.Valeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.    CANADA STOCKS-Resource shares, Valeant nudge TSX higherUPDATE 3-Valeant says improved bid for Allergan won't be all-cashValeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.  Valeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker. LAVAL, QUEBEC, May 20 Canada's Valeant Pharmaceuticals International said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.Valeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.   UPDATE 3-Valeant says improved bid for Allergan won't be all-cashValeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.  Valeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker. LAVAL, QUEBEC, May 20 Canada's Valeant Pharmaceuticals International said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.Valeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.  * TSX rises 25.67 points, or 0.18 percent, to 14,540.41     * Seven of the 10 main index sectors advance     * Valeant higher after commenting on Allergan bid plans      By John Tilak     TORONTO, May 20 Canada's main stock index climbed slightly on Tuesday as gains in materials and energy shares helped offset weakness in the financial sector.     Providing further support was a rise in shares of Valeant Pharmaceuticals International Inc after the drugmaker said its sweetened takeoveUPDATE 3-Valeant says improved bid for Allergan won't be all-cashValeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.  Valeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker. LAVAL, QUEBEC, May 20 Canada's Valeant Pharmaceuticals International said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.Valeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.   May 20 Canada's Valeant Pharmaceuticals International Inc said its sweetened offer for drugmaker Allergan Inc would not be an all-cash bid as was expected.CANADA STOCKS-Resource shares, Valeant nudge TSX higherUPDATE 3-Valeant says improved bid for Allergan won't be all-cashValeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.  Valeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker. LAVAL, QUEBEC, May 20 Canada's Valeant Pharmaceuticals International said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.Valeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.   UPDATE 3-Valeant says improved bid for Allergan won't be all-cashValeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.  Valeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker. LAVAL, QUEBEC, May 20 Canada's Valeant Pharmaceuticals International said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.Valeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.  * TSX rises 25.67 points, or 0.18 percent, to 14,540.41     * Seven of the 10 main index sectors advance     * Valeant higher after commenting on Allergan bid plans      By John Tilak     TORONTO, May 20 Canada's main stock index climbed slightly on Tuesday as gains in materials and energy shares helped offset weakness in the financial sector.     Providing further support was a rise in shares of Valeant Pharmaceuticals International Inc after the drugmaker said its sweetened takeoveUPDATE 3-Valeant says improved bid for Allergan won't be all-cashValeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.  Valeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker. LAVAL, QUEBEC, May 20 Canada's Valeant Pharmaceuticals International said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.Valeant says improved bid for Allergan won't be all-cash LAVAL, QUEBEC Canada's Valeant Pharmaceuticals International  said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc  as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.    
AJG,RSA to sell Canadian brokerage unit Noraxis for $460 mln May 20 British insurer RSA Insurance Group Plc  said on Monday it had reached agreement to sell its majority-owned Canadian brokerage business - Noraxis Capital Corp - to U.S. insurance brokerage Arthur J. Gallagher & Co  for C$500 million ($460.60 million). 
T,AT&T-DirecTV; merger may hinge on NFL agreement AT&T; Inc can pull out of its agreement to buy DirecTV if the satellite TV operator is unable to renew a deal with the National Football League to offer the popular NFL Sunday Ticket football package, according to a regulatory filing on Monday. |Â Video  
BA,Lockheed-Boeing venture says rocket launch costs lower than claimed by rivalLockheed-Boeing venture says rocket launch costs lower than claimed by rivalLockheed-Boeing venture says rocket launch costs lower than claimed by rival COLORADO SPRINGS Colo. A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.  Lockheed-Boeing venture says rocket launch costs lower than claimed by rival COLORADO SPRINGS Colo. A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business. COLORADO SPRINGS, Colo. A joint venture of Lockheed Martin Corp  and Boeing Co  on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.Lockheed-Boeing venture says rocket launch costs lower than claimed by rival COLORADO SPRINGS Colo. A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.   Lockheed-Boeing venture says rocket launch costs lower than claimed by rivalLockheed-Boeing venture says rocket launch costs lower than claimed by rival COLORADO SPRINGS Colo. A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.  Lockheed-Boeing venture says rocket launch costs lower than claimed by rival COLORADO SPRINGS Colo. A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business. COLORADO SPRINGS, Colo. A joint venture of Lockheed Martin Corp  and Boeing Co  on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.Lockheed-Boeing venture says rocket launch costs lower than claimed by rival COLORADO SPRINGS Colo. A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.  COLORADO SPRINGS, Colo., May 19 A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.Lockheed-Boeing venture says rocket launch costs lower than claimed by rivalLockheed-Boeing venture says rocket launch costs lower than claimed by rival COLORADO SPRINGS Colo. A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.  Lockheed-Boeing venture says rocket launch costs lower than claimed by rival COLORADO SPRINGS Colo. A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business. COLORADO SPRINGS, Colo. A joint venture of Lockheed Martin Corp  and Boeing Co  on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.Lockheed-Boeing venture says rocket launch costs lower than claimed by rival COLORADO SPRINGS Colo. A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.   
C,CD&R; in advanced talks to buy Healogics for about $1 bln -sources NEW YORK, May 20 Clayton, Dubilier & Rice LLC is in advanced talks to acquire wound care company Healogics Inc from private equity peer Metalmark Capital Holdings LLC for around $1 billion, according to people familiar with the matter. 
CAG,UPDATE 2-U.S. approves deal that makes biggest flour miller even bigger (Adds comment from a critic of the approval, details on flour market, paragraphs 9-11) 
EW,Medtronic settles heart valve patent dispute with EdwardsUPDATE 3-Medtronic settles heart valve patent fight with rival Edwards May 20 Medtronic Inc agreed to pay more than $1 billion to rival Edwards Lifesciences Corp to settle patent litigation and keep its CoreValve artificial heart valve on the U.S. market.  UPDATE 3-Medtronic settles heart valve patent fight with rival Edwards May 20 Medtronic Inc agreed to pay more than $1 billion to rival Edwards Lifesciences Corp to settle patent litigation and keep its CoreValve artificial heart valve on the U.S. market. May 20 Medtronic Inc on Tuesday said it has agreed to pay royalties to rival medical device maker Edwards Lifesciences Corp in a settlement agreement that allows Medtronic to continue to sell its CoreValve replacement heart valves.UPDATE 3-Medtronic settles heart valve patent fight with rival Edwards May 20 Medtronic Inc agreed to pay more than $1 billion to rival Edwards Lifesciences Corp to settle patent litigation and keep its CoreValve artificial heart valve on the U.S. market.  
XOM,Exxon's Papua New Guinea LNG plant to export 20 cargoes by Sept MILAN, May 20 ExxonMobil's Papua New Guinea gas liquefaction plant is expected to export around 20 cargoes during the project's start-up phase lasting until September, traders said. 
FIS,REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects Pfizer (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph) 
F,Obama to discuss U.S. investment with corporate executivesObama to discuss U.S. investment with corporate executivesUPDATE 1-Obama discusses U.S. investment with corporate executives WASHINGTON, May 20 President Barack Obama gathered executives from several major international companies on Tuesday, including Ford Motor Co and Deutshe Lufthansa AG, to discuss a White House initiative to encourage investment in the United States.  UPDATE 1-Obama discusses U.S. investment with corporate executives WASHINGTON, May 20 President Barack Obama gathered executives from several major international companies on Tuesday, including Ford Motor Co and Deutshe Lufthansa AG, to discuss a White House initiative to encourage investment in the United States. WASHINGTON President Barack Obama will gather executives from several major international companies including Ford Motor Co and Deutshe Lufthansa AG on Tuesday to discuss a White House initiative to encourage investment in the United States.UPDATE 1-Obama discusses U.S. investment with corporate executives WASHINGTON, May 20 President Barack Obama gathered executives from several major international companies on Tuesday, including Ford Motor Co and Deutshe Lufthansa AG, to discuss a White House initiative to encourage investment in the United States.   Obama to discuss U.S. investment with corporate executivesUPDATE 1-Obama discusses U.S. investment with corporate executives WASHINGTON, May 20 President Barack Obama gathered executives from several major international companies on Tuesday, including Ford Motor Co and Deutshe Lufthansa AG, to discuss a White House initiative to encourage investment in the United States.  UPDATE 1-Obama discusses U.S. investment with corporate executives WASHINGTON, May 20 President Barack Obama gathered executives from several major international companies on Tuesday, including Ford Motor Co and Deutshe Lufthansa AG, to discuss a White House initiative to encourage investment in the United States. WASHINGTON President Barack Obama will gather executives from several major international companies including Ford Motor Co and Deutshe Lufthansa AG on Tuesday to discuss a White House initiative to encourage investment in the United States.UPDATE 1-Obama discusses U.S. investment with corporate executives WASHINGTON, May 20 President Barack Obama gathered executives from several major international companies on Tuesday, including Ford Motor Co and Deutshe Lufthansa AG, to discuss a White House initiative to encourage investment in the United States.  WASHINGTON, May 20 President Barack Obama will gather executives from several major international companies including Ford Motor Co and Deutshe Lufthansa AG  on Tuesday to discuss a White House initiative to encourage investment in the United States.Obama to discuss U.S. investment with corporate executivesUPDATE 1-Obama discusses U.S. investment with corporate executives WASHINGTON, May 20 President Barack Obama gathered executives from several major international companies on Tuesday, including Ford Motor Co and Deutshe Lufthansa AG, to discuss a White House initiative to encourage investment in the United States.  UPDATE 1-Obama discusses U.S. investment with corporate executives WASHINGTON, May 20 President Barack Obama gathered executives from several major international companies on Tuesday, including Ford Motor Co and Deutshe Lufthansa AG, to discuss a White House initiative to encourage investment in the United States. WASHINGTON President Barack Obama will gather executives from several major international companies including Ford Motor Co and Deutshe Lufthansa AG on Tuesday to discuss a White House initiative to encourage investment in the United States.UPDATE 1-Obama discusses U.S. investment with corporate executives WASHINGTON, May 20 President Barack Obama gathered executives from several major international companies on Tuesday, including Ford Motor Co and Deutshe Lufthansa AG, to discuss a White House initiative to encourage investment in the United States.   
GE,Siemens asks Alstom for more info ahead of likely offer: minister PARIS Germany's Siemens  wrote to Alstom  on Tuesday asking for more information ahead of a likely offer for the French company's power business, French Economy Minister Arnaud Montebourg said. 
GM,BRIEF-GM recalls another 2.42 million vehicles in four U.S. recallsGM recalls another 2.42 mln vehicles, doubles 2nd quarter charge DETROIT, May 20 General Motors Co said on Tuesday it is recalling another 2.42 million vehicles in the United States, raising the number of vehicles it has recalled so far this year to more than 15 million.  GM recalls another 2.42 mln vehicles, doubles 2nd quarter charge DETROIT, May 20 General Motors Co said on Tuesday it is recalling another 2.42 million vehicles in the United States, raising the number of vehicles it has recalled so far this year to more than 15 million. DETROIT, May 20 General Motors Co :  * Says recalling about 2.42 million vehicles in four U.S. recalls  * Says no fatalities associated with any of the recalls  * Says largest recall covers 1.3 million full-size crossover vehicles forGM recalls another 2.42 mln vehicles, doubles 2nd quarter charge DETROIT, May 20 General Motors Co said on Tuesday it is recalling another 2.42 million vehicles in the United States, raising the number of vehicles it has recalled so far this year to more than 15 million.  
GILD,U.S. health insurers say Gilead hepatitis C drug too costlyUPDATE 1-U.S. health insurers say Gilead hepatitis C drug too costly May 20 The leading U.S. health insurance trade group on Tuesday hit out at the extremely high cost of new specialty medicines, accusing drugmakers of taking advantage of the insurance system by pricing products at unsustainable levels.  UPDATE 1-U.S. health insurers say Gilead hepatitis C drug too costly May 20 The leading U.S. health insurance trade group on Tuesday hit out at the extremely high cost of new specialty medicines, accusing drugmakers of taking advantage of the insurance system by pricing products at unsustainable levels. May 20 The leading U.S. health insurance trade group on Tuesday hit out at the extremely high cost of new specialty medicines, accusing drugmakers of taking advantage of the insurance system by pricing products at unsustainable levels.UPDATE 1-U.S. health insurers say Gilead hepatitis C drug too costly May 20 The leading U.S. health insurance trade group on Tuesday hit out at the extremely high cost of new specialty medicines, accusing drugmakers of taking advantage of the insurance system by pricing products at unsustainable levels.  
GS,RPT-Deutsche Bank chairman leads battle for the bulge bracketGoldman confirms formal sale of Metro metals warehousing unitCD&R; in advanced talks to buy Healogics for about $1 bln -sources NEW YORK, May 20 Clayton, Dubilier & Rice LLC is in advanced talks to acquire wound care company Healogics Inc from private equity peer Metalmark Capital Holdings LLC for around $1 billion, according to people familiar with the matter.  CD&R; in advanced talks to buy Healogics for about $1 bln -sources NEW YORK, May 20 Clayton, Dubilier & Rice LLC is in advanced talks to acquire wound care company Healogics Inc from private equity peer Metalmark Capital Holdings LLC for around $1 billion, according to people familiar with the matter. NEW YORK, May 20 Goldman Sachs has begun a formal process to sell the metals warehousing business it purchased four years ago, a spokesman said on Tuesday, confirming an earlier Reuters report.CD&R; in advanced talks to buy Healogics for about $1 bln -sources NEW YORK, May 20 Clayton, Dubilier & Rice LLC is in advanced talks to acquire wound care company Healogics Inc from private equity peer Metalmark Capital Holdings LLC for around $1 billion, according to people familiar with the matter.   Goldman confirms formal sale of Metro metals warehousing unitCD&R; in advanced talks to buy Healogics for about $1 bln -sources NEW YORK, May 20 Clayton, Dubilier & Rice LLC is in advanced talks to acquire wound care company Healogics Inc from private equity peer Metalmark Capital Holdings LLC for around $1 billion, according to people familiar with the matter.  CD&R; in advanced talks to buy Healogics for about $1 bln -sources NEW YORK, May 20 Clayton, Dubilier & Rice LLC is in advanced talks to acquire wound care company Healogics Inc from private equity peer Metalmark Capital Holdings LLC for around $1 billion, according to people familiar with the matter. NEW YORK, May 20 Goldman Sachs has begun a formal process to sell the metals warehousing business it purchased four years ago, a spokesman said on Tuesday, confirming an earlier Reuters report.CD&R; in advanced talks to buy Healogics for about $1 bln -sources NEW YORK, May 20 Clayton, Dubilier & Rice LLC is in advanced talks to acquire wound care company Healogics Inc from private equity peer Metalmark Capital Holdings LLC for around $1 billion, according to people familiar with the matter.  * Deutsche aims to remain a global investment bank playerGoldman confirms formal sale of Metro metals warehousing unitCD&R; in advanced talks to buy Healogics for about $1 bln -sources NEW YORK, May 20 Clayton, Dubilier & Rice LLC is in advanced talks to acquire wound care company Healogics Inc from private equity peer Metalmark Capital Holdings LLC for around $1 billion, according to people familiar with the matter.  CD&R; in advanced talks to buy Healogics for about $1 bln -sources NEW YORK, May 20 Clayton, Dubilier & Rice LLC is in advanced talks to acquire wound care company Healogics Inc from private equity peer Metalmark Capital Holdings LLC for around $1 billion, according to people familiar with the matter. NEW YORK, May 20 Goldman Sachs has begun a formal process to sell the metals warehousing business it purchased four years ago, a spokesman said on Tuesday, confirming an earlier Reuters report.CD&R; in advanced talks to buy Healogics for about $1 bln -sources NEW YORK, May 20 Clayton, Dubilier & Rice LLC is in advanced talks to acquire wound care company Healogics Inc from private equity peer Metalmark Capital Holdings LLC for around $1 billion, according to people familiar with the matter.   
HD,Home Depot's first-quarter sales rise 2.9 pctUS STOCKS-Futures flat after two-day gain; Staples, Home Depot fallCORRECTED-UPDATE 2-Slow start to spring selling season hurts Home Depot salesUS STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices)  US STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices) (Corrects first bullet point and adds paragraph 17 to reflect that the company's profit, excluding a benefit from a share sale, is comparable with average analyst estimate)US STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices)   CORRECTED-UPDATE 2-Slow start to spring selling season hurts Home Depot salesUS STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices)  US STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices) (Corrects first bullet point and adds paragraph 17 to reflect that the company's profit, excluding a benefit from a share sale, is comparable with average analyst estimate)US STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices)  * More AstraZeneca investors disprove of Pfizer rejectionCORRECTED-UPDATE 2-Slow start to spring selling season hurts Home Depot salesUS STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices)  US STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices) (Corrects first bullet point and adds paragraph 17 to reflect that the company's profit, excluding a benefit from a share sale, is comparable with average analyst estimate)US STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices)    US STOCKS-Futures flat after two-day gain; Staples, Home Depot fallCORRECTED-UPDATE 2-Slow start to spring selling season hurts Home Depot salesUS STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices)  US STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices) (Corrects first bullet point and adds paragraph 17 to reflect that the company's profit, excluding a benefit from a share sale, is comparable with average analyst estimate)US STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices)   CORRECTED-UPDATE 2-Slow start to spring selling season hurts Home Depot salesUS STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices)  US STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices) (Corrects first bullet point and adds paragraph 17 to reflect that the company's profit, excluding a benefit from a share sale, is comparable with average analyst estimate)US STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices)  * More AstraZeneca investors disprove of Pfizer rejectionCORRECTED-UPDATE 2-Slow start to spring selling season hurts Home Depot salesUS STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices)  US STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices) (Corrects first bullet point and adds paragraph 17 to reflect that the company's profit, excluding a benefit from a share sale, is comparable with average analyst estimate)US STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices)   May 20 Home Depot Inc, the world's largest home improvement chain, reported a 2.9 percent rise in quarterly sales as its spring selling season got off to a slow start.US STOCKS-Futures flat after two-day gain; Staples, Home Depot fallCORRECTED-UPDATE 2-Slow start to spring selling season hurts Home Depot salesUS STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices)  US STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices) (Corrects first bullet point and adds paragraph 17 to reflect that the company's profit, excluding a benefit from a share sale, is comparable with average analyst estimate)US STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices)   CORRECTED-UPDATE 2-Slow start to spring selling season hurts Home Depot salesUS STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices)  US STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices) (Corrects first bullet point and adds paragraph 17 to reflect that the company's profit, excluding a benefit from a share sale, is comparable with average analyst estimate)US STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices)  * More AstraZeneca investors disprove of Pfizer rejectionCORRECTED-UPDATE 2-Slow start to spring selling season hurts Home Depot salesUS STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices)  US STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices) (Corrects first bullet point and adds paragraph 17 to reflect that the company's profit, excluding a benefit from a share sale, is comparable with average analyst estimate)US STOCKS-Wall St to open flat after two-day gain; Home Depot down * Futures off: Dow 9 pts, S&P; 1.3 pts, Nasdaq 1 pt   (Adds Dick's earnings, Morning Call link, updates prices)    
JPM,UPDATE 3-EU Commission charges HSBC, JPMorgan, Credit Agricole with riggingEU Commission charges HSBC, JPMorgan, Credit Agricole with riggingDIARY-U.S. MEETINGS/WEEK AHEADUPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)      UPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     THOMSON REUTERS, May 20,2014 - Corporate Meetings for US companies for Week ahead.         S&P; 500 Earnings - Weekly           S&P; 500 Earnings - Day Ahead        Non S&P; 500 - Weekly               Non S&P; 500 - Day Ahead             ConferenceCall/Webcast - Weekly    ConferenceCall/Webcast - Day        S&P; 500 Earnings - Monthly           Meetings - Day Ahead                Economic Indicators                  Dividends                           Daily earnings hits & misses         Federal ReseUPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)       DIARY-U.S. MEETINGS/WEEK AHEADUPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)      UPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     THOMSON REUTERS, May 20,2014 - Corporate Meetings for US companies for Week ahead.         S&P; 500 Earnings - Weekly           S&P; 500 Earnings - Day Ahead        Non S&P; 500 - Weekly               Non S&P; 500 - Day Ahead             ConferenceCall/Webcast - Weekly    ConferenceCall/Webcast - Day        S&P; 500 Earnings - Monthly           Meetings - Day Ahead                Economic Indicators                  Dividends                           Daily earnings hits & misses         Federal ReseUPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)      BRUSSELS European Union antitrust regulators charged Europe's biggest bank HSBC, U.S. peer JPMorgan and France's Credit Agricole on Tuesday with rigging financial benchmarks linked to the euro, exposing them to potential fines.DIARY-U.S. MEETINGS/WEEK AHEADUPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)      UPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     THOMSON REUTERS, May 20,2014 - Corporate Meetings for US companies for Week ahead.         S&P; 500 Earnings - Weekly           S&P; 500 Earnings - Day Ahead        Non S&P; 500 - Weekly               Non S&P; 500 - Day Ahead             ConferenceCall/Webcast - Weekly    ConferenceCall/Webcast - Day        S&P; 500 Earnings - Monthly           Meetings - Day Ahead                Economic Indicators                  Dividends                           Daily earnings hits & misses         Federal ReseUPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)        EU Commission charges HSBC, JPMorgan, Credit Agricole with riggingDIARY-U.S. MEETINGS/WEEK AHEADUPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)      UPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     THOMSON REUTERS, May 20,2014 - Corporate Meetings for US companies for Week ahead.         S&P; 500 Earnings - Weekly           S&P; 500 Earnings - Day Ahead        Non S&P; 500 - Weekly               Non S&P; 500 - Day Ahead             ConferenceCall/Webcast - Weekly    ConferenceCall/Webcast - Day        S&P; 500 Earnings - Monthly           Meetings - Day Ahead                Economic Indicators                  Dividends                           Daily earnings hits & misses         Federal ReseUPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)       DIARY-U.S. MEETINGS/WEEK AHEADUPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)      UPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     THOMSON REUTERS, May 20,2014 - Corporate Meetings for US companies for Week ahead.         S&P; 500 Earnings - Weekly           S&P; 500 Earnings - Day Ahead        Non S&P; 500 - Weekly               Non S&P; 500 - Day Ahead             ConferenceCall/Webcast - Weekly    ConferenceCall/Webcast - Day        S&P; 500 Earnings - Monthly           Meetings - Day Ahead                Economic Indicators                  Dividends                           Daily earnings hits & misses         Federal ReseUPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)      BRUSSELS European Union antitrust regulators charged Europe's biggest bank HSBC, U.S. peer JPMorgan and France's Credit Agricole on Tuesday with rigging financial benchmarks linked to the euro, exposing them to potential fines.DIARY-U.S. MEETINGS/WEEK AHEADUPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)      UPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     THOMSON REUTERS, May 20,2014 - Corporate Meetings for US companies for Week ahead.         S&P; 500 Earnings - Weekly           S&P; 500 Earnings - Day Ahead        Non S&P; 500 - Weekly               Non S&P; 500 - Day Ahead             ConferenceCall/Webcast - Weekly    ConferenceCall/Webcast - Day        S&P; 500 Earnings - Monthly           Meetings - Day Ahead                Economic Indicators                  Dividends                           Daily earnings hits & misses         Federal ReseUPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)       BRUSSELS, May 20 European Union antitrust regulators charged Europe's biggest bank HSBC, U.S. peer JPMorgan and France's Credit Agricole on Tuesday with rigging financial benchmarks linked to the euro, exposing them to potential fines.EU Commission charges HSBC, JPMorgan, Credit Agricole with riggingDIARY-U.S. MEETINGS/WEEK AHEADUPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)      UPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     THOMSON REUTERS, May 20,2014 - Corporate Meetings for US companies for Week ahead.         S&P; 500 Earnings - Weekly           S&P; 500 Earnings - Day Ahead        Non S&P; 500 - Weekly               Non S&P; 500 - Day Ahead             ConferenceCall/Webcast - Weekly    ConferenceCall/Webcast - Day        S&P; 500 Earnings - Monthly           Meetings - Day Ahead                Economic Indicators                  Dividends                           Daily earnings hits & misses         Federal ReseUPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)       DIARY-U.S. MEETINGS/WEEK AHEADUPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)      UPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     THOMSON REUTERS, May 20,2014 - Corporate Meetings for US companies for Week ahead.         S&P; 500 Earnings - Weekly           S&P; 500 Earnings - Day Ahead        Non S&P; 500 - Weekly               Non S&P; 500 - Day Ahead             ConferenceCall/Webcast - Weekly    ConferenceCall/Webcast - Day        S&P; 500 Earnings - Monthly           Meetings - Day Ahead                Economic Indicators                  Dividends                           Daily earnings hits & misses         Federal ReseUPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)      BRUSSELS European Union antitrust regulators charged Europe's biggest bank HSBC, U.S. peer JPMorgan and France's Credit Agricole on Tuesday with rigging financial benchmarks linked to the euro, exposing them to potential fines.DIARY-U.S. MEETINGS/WEEK AHEADUPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)      UPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     THOMSON REUTERS, May 20,2014 - Corporate Meetings for US companies for Week ahead.         S&P; 500 Earnings - Weekly           S&P; 500 Earnings - Day Ahead        Non S&P; 500 - Weekly               Non S&P; 500 - Day Ahead             ConferenceCall/Webcast - Weekly    ConferenceCall/Webcast - Day        S&P; 500 Earnings - Monthly           Meetings - Day Ahead                Economic Indicators                  Dividends                           Daily earnings hits & misses         Federal ReseUPDATE 2-JP Morgan exec killed himself leaping from UK building, inquest rulesJP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)     JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    * Notes saying "jump" were found on his computer   (Adds ruling, JP Morgan evidence to inquest)JP Morgan exec killed himself leaping from UK building, inquest rulesJPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)    JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   LONDON A JP Morgan technology expert who fell to his death from the bank's tower in London's Canary Wharf financial district, killed himself, an inquest concluded on Tuesday.JPMorgan Chase shareholders back directors, executive payUPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)   UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  TAMPA, Florida, May 20 Shareholders of JPMorgan Chase & Co voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed the company's payments to executives in 2013.UPDATE 1-JPMorgan Chase shareholders back directors, executive payREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)  REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated) TAMPA, Florida, May 20 JPMorgan Chase & Co  shareholders voted overwhelmingly on Tuesday to elect all of the company's directors and also endorsed its compensation to executives in 2013.REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in fees (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)        
LMT,Lockheed-Boeing venture says rocket launch costs lower than claimed by rivalLockheed-Boeing venture says rocket launch costs lower than claimed by rivalLockheed-Boeing venture says rocket launch costs lower than claimed by rivalLockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday.  Lockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday. COLORADO SPRINGS Colo. A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.Lockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday.   Lockheed-Boeing venture says rocket launch costs lower than claimed by rivalLockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday.  Lockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday. COLORADO SPRINGS Colo. A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.Lockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday.  COLORADO SPRINGS, Colo. A joint venture of Lockheed Martin Corp  and Boeing Co  on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.Lockheed-Boeing venture says rocket launch costs lower than claimed by rivalLockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday.  Lockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday. COLORADO SPRINGS Colo. A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.Lockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday.    Lockheed-Boeing venture says rocket launch costs lower than claimed by rivalLockheed-Boeing venture says rocket launch costs lower than claimed by rivalLockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday.  Lockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday. COLORADO SPRINGS Colo. A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.Lockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday.   Lockheed-Boeing venture says rocket launch costs lower than claimed by rivalLockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday.  Lockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday. COLORADO SPRINGS Colo. A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.Lockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday.  COLORADO SPRINGS, Colo. A joint venture of Lockheed Martin Corp  and Boeing Co  on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.Lockheed-Boeing venture says rocket launch costs lower than claimed by rivalLockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday.  Lockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday. COLORADO SPRINGS Colo. A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.Lockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday.   COLORADO SPRINGS, Colo., May 19 A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.Lockheed-Boeing venture says rocket launch costs lower than claimed by rivalLockheed-Boeing venture says rocket launch costs lower than claimed by rivalLockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday.  Lockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday. COLORADO SPRINGS Colo. A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.Lockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday.   Lockheed-Boeing venture says rocket launch costs lower than claimed by rivalLockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday.  Lockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday. COLORADO SPRINGS Colo. A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.Lockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday.  COLORADO SPRINGS, Colo. A joint venture of Lockheed Martin Corp  and Boeing Co  on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.Lockheed-Boeing venture says rocket launch costs lower than claimed by rivalLockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday.  Lockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday. COLORADO SPRINGS Colo. A joint venture of Lockheed Martin Corp and Boeing Co on Monday said its rocket launch costs were far lower than claimed by its rival, privately-held Space Exploration Technologies, or SpaceX, which is suing the U.S. government for shutting it out of the lucrative rocket launch business.Lockheed machinists at Mississippi space center vote to end strike WASHINGTON, May 20 Lockheed Martin Corp  said on Tuesday that more than 100 union members who had been on strike at a Mississippi space center since late last week voted to accept the company's contract offer and would return to work on Wednesday.    
MCD,REFILE-McDonald's new 'Happy' mascot dubbed McScary in social media CHICAGO, May 20 McDonald's restaurant chain says its new "Happy" mascot will bring "fun and excitement" to its children's meals, but social media contend the toothy, red box-shaped character will have the opposite effect. 
MDT,Medtronic settles heart valve patent dispute with EdwardsUPDATE 3-Medtronic settles heart valve patent fight with rival Edwards May 20 Medtronic Inc agreed to pay more than $1 billion to rival Edwards Lifesciences Corp to settle patent litigation and keep its CoreValve artificial heart valve on the U.S. market.  UPDATE 3-Medtronic settles heart valve patent fight with rival Edwards May 20 Medtronic Inc agreed to pay more than $1 billion to rival Edwards Lifesciences Corp to settle patent litigation and keep its CoreValve artificial heart valve on the U.S. market. May 20 Medtronic Inc on Tuesday said it has agreed to pay royalties to rival medical device maker Edwards Lifesciences Corp in a settlement agreement that allows Medtronic to continue to sell its CoreValve replacement heart valves.UPDATE 3-Medtronic settles heart valve patent fight with rival Edwards May 20 Medtronic Inc agreed to pay more than $1 billion to rival Edwards Lifesciences Corp to settle patent litigation and keep its CoreValve artificial heart valve on the U.S. market.  
MSFT,China bans use of Microsoft's Windows 8 on government computersMicrosoft shows off new, larger Surface Pro tabletUPDATE 1-China bans use of Microsoft's Windows 8 on gov't computersChina bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.  China bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country. BEIJING, May 20 China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.China bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.   UPDATE 1-China bans use of Microsoft's Windows 8 on gov't computersChina bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.  China bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country. BEIJING, May 20 China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.China bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.  NEW YORK, May 20 Microsoft Corp on Tuesday unveiled a larger but lighter version of its Surface Pro tablet as it ramps up efforts to make an impact on the mobile computing market and counter the popularity of Apple Inc's  iPad and MacBook Air laptop.UPDATE 1-China bans use of Microsoft's Windows 8 on gov't computersChina bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.  China bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country. BEIJING, May 20 China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.China bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.    Microsoft shows off new, larger Surface Pro tabletUPDATE 1-China bans use of Microsoft's Windows 8 on gov't computersChina bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.  China bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country. BEIJING, May 20 China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.China bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.   UPDATE 1-China bans use of Microsoft's Windows 8 on gov't computersChina bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.  China bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country. BEIJING, May 20 China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.China bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.  NEW YORK, May 20 Microsoft Corp on Tuesday unveiled a larger but lighter version of its Surface Pro tablet as it ramps up efforts to make an impact on the mobile computing market and counter the popularity of Apple Inc's  iPad and MacBook Air laptop.UPDATE 1-China bans use of Microsoft's Windows 8 on gov't computersChina bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.  China bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country. BEIJING, May 20 China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.China bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.   BEIJING, May 20 China has banned government use of Windows 8, Microsoft Corp's latest operating system (OS), in a blow to the U.S. technology company which has long been plagued by sales woes in the country.Microsoft shows off new, larger Surface Pro tabletUPDATE 1-China bans use of Microsoft's Windows 8 on gov't computersChina bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.  China bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country. BEIJING, May 20 China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.China bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.   UPDATE 1-China bans use of Microsoft's Windows 8 on gov't computersChina bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.  China bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country. BEIJING, May 20 China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.China bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.  NEW YORK, May 20 Microsoft Corp on Tuesday unveiled a larger but lighter version of its Surface Pro tablet as it ramps up efforts to make an impact on the mobile computing market and counter the popularity of Apple Inc's  iPad and MacBook Air laptop.UPDATE 1-China bans use of Microsoft's Windows 8 on gov't computersChina bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.  China bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country. BEIJING, May 20 China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.China bans use of Microsoft's Windows 8 on government computers BEIJING China has banned government use of Windows 8, Microsoft Corp's latest operating system, a blow to a U.S. technology company that has long struggled with sales in the country.    
PFE,AstraZeneca "did the right thing" rejecting Pfizer - FidelityAstraZeneca 'did the right thing' rejecting Pfizer: FidelityCORRECTED-US STOCKS-Wall Street dips as retailer earnings disappointAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.       AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      (Corrects name of chain store in second line of second paragraph to TJ Maxx from TJX Maxx.)AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.        CORRECTED-US STOCKS-Wall Street dips as retailer earnings disappointAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.       AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      (Corrects name of chain store in second line of second paragraph to TJ Maxx from TJX Maxx.)AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.       LONDON Fidelity Worldwide Investment, which holds around 1.2 percent of AstraZeneca  has come out in support of the drugs giant's rejection of a $118 takeover bid by Pfizer .CORRECTED-US STOCKS-Wall Street dips as retailer earnings disappointAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.       AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      (Corrects name of chain store in second line of second paragraph to TJ Maxx from TJX Maxx.)AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.         AstraZeneca 'did the right thing' rejecting Pfizer: FidelityCORRECTED-US STOCKS-Wall Street dips as retailer earnings disappointAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.       AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      (Corrects name of chain store in second line of second paragraph to TJ Maxx from TJX Maxx.)AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.        CORRECTED-US STOCKS-Wall Street dips as retailer earnings disappointAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.       AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      (Corrects name of chain store in second line of second paragraph to TJ Maxx from TJX Maxx.)AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.       LONDON Fidelity Worldwide Investment, which holds around 1.2 percent of AstraZeneca  has come out in support of the drugs giant's rejection of a $118 takeover bid by Pfizer .CORRECTED-US STOCKS-Wall Street dips as retailer earnings disappointAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.       AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      (Corrects name of chain store in second line of second paragraph to TJ Maxx from TJX Maxx.)AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.        LONDON, May 20 Fidelity Worldwide Investment, which holds around 1.2 percent of AstraZeneca has come out in support of the drugs giant's rejection of a $118 takeover bid by Pfizer.AstraZeneca 'did the right thing' rejecting Pfizer: FidelityCORRECTED-US STOCKS-Wall Street dips as retailer earnings disappointAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.       AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      (Corrects name of chain store in second line of second paragraph to TJ Maxx from TJX Maxx.)AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.        CORRECTED-US STOCKS-Wall Street dips as retailer earnings disappointAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.       AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      (Corrects name of chain store in second line of second paragraph to TJ Maxx from TJX Maxx.)AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.       LONDON Fidelity Worldwide Investment, which holds around 1.2 percent of AstraZeneca  has come out in support of the drugs giant's rejection of a $118 takeover bid by Pfizer .CORRECTED-US STOCKS-Wall Street dips as retailer earnings disappointAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.       AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      (Corrects name of chain store in second line of second paragraph to TJ Maxx from TJX Maxx.)AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesAstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.      AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     LONDON, May 20 British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.AstraZeneca says no negotiation with suitor Pfizer allowed under UK rulesREFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.     REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    LONDON British drugmaker AstraZeneca  said that there could be no further negotiation with U.S. suitor Pfizer  on the value of a takeover proposal, in a statement which it said it issued to clarify the situation under UK takeover rules.REFILE-UPDATE 3-Schroders, Fidelity reveal investor split as Astra rejects PfizerUPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.    UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   (Inserts full name of London-based Fidelity Worldwide Investment in lead paragraph)UPDATE 4-Schroders, Fidelity reveal investor split as Astra rejects PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.   REFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  * Schroders urges AstraZeneca to restart talks with PfizerREFILE-Pfizer-AstraZeneca bankers set to miss up to $340 mln in feesPfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.  Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday. (Adds context in paragraph 3 to clarify fees are unlikely in event deal is not consummated)Pfizer-AstraZeneca bankers set to miss up to $340 million in fees LONDON Bankers advising pharmaceuticals companies Pfizer  and Britain's AstraZeneca  are likely to miss out on $260-340 million in fees after the U.S. company's final takeover bid was rejected on Monday.         
CRM,Salesforce.com revenue beats estimates May 20 Salesforce.com Inc reported a better-than-expected 37 percent rise in quarterly revenue, helped by higher demand for its sales and marketing software. 
SPLS,Staples profit falls 44 pct on stronger dollar, store closuresUS STOCKS-Futures flat after two-day gain; Staples, Home Depot fallUS STOCKS-Wall St falls as retailers, Caterpillar weighUPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003.  UPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003. * Dow off 0.9 pct; S&P; 500 down 0.7 pct; Nasdaq off 0.8 pct   (Updates to midday trading, adds GM recall)UPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003.   US STOCKS-Wall St falls as retailers, Caterpillar weighUPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003.  UPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003. * Dow off 0.9 pct; S&P; 500 down 0.7 pct; Nasdaq off 0.8 pct   (Updates to midday trading, adds GM recall)UPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003.  * More AstraZeneca investors disprove of Pfizer rejectionUS STOCKS-Wall St falls as retailers, Caterpillar weighUPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003.  UPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003. * Dow off 0.9 pct; S&P; 500 down 0.7 pct; Nasdaq off 0.8 pct   (Updates to midday trading, adds GM recall)UPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003.    US STOCKS-Futures flat after two-day gain; Staples, Home Depot fallUS STOCKS-Wall St falls as retailers, Caterpillar weighUPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003.  UPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003. * Dow off 0.9 pct; S&P; 500 down 0.7 pct; Nasdaq off 0.8 pct   (Updates to midday trading, adds GM recall)UPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003.   US STOCKS-Wall St falls as retailers, Caterpillar weighUPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003.  UPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003. * Dow off 0.9 pct; S&P; 500 down 0.7 pct; Nasdaq off 0.8 pct   (Updates to midday trading, adds GM recall)UPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003.  * More AstraZeneca investors disprove of Pfizer rejectionUS STOCKS-Wall St falls as retailers, Caterpillar weighUPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003.  UPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003. * Dow off 0.9 pct; S&P; 500 down 0.7 pct; Nasdaq off 0.8 pct   (Updates to midday trading, adds GM recall)UPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003.   May 20 Office supply retailer Staples Inc  reported a 44 percent fall in quarterly profit, hurt by a stronger U.S. dollar and store closures.US STOCKS-Futures flat after two-day gain; Staples, Home Depot fallUS STOCKS-Wall St falls as retailers, Caterpillar weighUPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003.  UPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003. * Dow off 0.9 pct; S&P; 500 down 0.7 pct; Nasdaq off 0.8 pct   (Updates to midday trading, adds GM recall)UPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003.   US STOCKS-Wall St falls as retailers, Caterpillar weighUPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003.  UPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003. * Dow off 0.9 pct; S&P; 500 down 0.7 pct; Nasdaq off 0.8 pct   (Updates to midday trading, adds GM recall)UPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003.  * More AstraZeneca investors disprove of Pfizer rejectionUS STOCKS-Wall St falls as retailers, Caterpillar weighUPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003.  UPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003. * Dow off 0.9 pct; S&P; 500 down 0.7 pct; Nasdaq off 0.8 pct   (Updates to midday trading, adds GM recall)UPDATE 3-Staples warns of falling sales, shares slump May 20 Staples Inc forecast a fall in sales in the current quarter as customers shift to e-retailers, mass merchants and drugstores to buy their office supplies, and the company reported its weakest quarterly gross margins since May 2003.    
TGT,Target names new head of troubled Canadian operationsUPDATE 3-Target replaces president of money-losing Canadian unit * Target replaces Canadian president with 15-year U.S. veteran  UPDATE 3-Target replaces president of money-losing Canadian unit * Target replaces Canadian president with 15-year U.S. veteran May 20 Target Corp replaced the head of its troubled Canadian operations, two weeks after the ousting of Chief Executive and Chairman Gregg Steinhafel.UPDATE 3-Target replaces president of money-losing Canadian unit * Target replaces Canadian president with 15-year U.S. veteran  
TJX,CORRECTED-Retailer TJX posts lower-than-expected quarterly salesCORRECTED-US STOCKS-Wall Street dips as retailer earnings disappointUPDATE 1-Retailer TJX cuts full-year earnings forecast; shares fall * Lowers top-end of profit outlook to $3.17/share from $3.19  UPDATE 1-Retailer TJX cuts full-year earnings forecast; shares fall * Lowers top-end of profit outlook to $3.17/share from $3.19 (Corrects name of chain store in second line of second paragraph to TJ Maxx from TJX Maxx.)UPDATE 1-Retailer TJX cuts full-year earnings forecast; shares fall * Lowers top-end of profit outlook to $3.17/share from $3.19   CORRECTED-US STOCKS-Wall Street dips as retailer earnings disappointUPDATE 1-Retailer TJX cuts full-year earnings forecast; shares fall * Lowers top-end of profit outlook to $3.17/share from $3.19  UPDATE 1-Retailer TJX cuts full-year earnings forecast; shares fall * Lowers top-end of profit outlook to $3.17/share from $3.19 (Corrects name of chain store in second line of second paragraph to TJ Maxx from TJX Maxx.)UPDATE 1-Retailer TJX cuts full-year earnings forecast; shares fall * Lowers top-end of profit outlook to $3.17/share from $3.19  (Corrects name of chain in paragraph 1 to TJ Maxx from TJX Maxx)CORRECTED-US STOCKS-Wall Street dips as retailer earnings disappointUPDATE 1-Retailer TJX cuts full-year earnings forecast; shares fall * Lowers top-end of profit outlook to $3.17/share from $3.19  UPDATE 1-Retailer TJX cuts full-year earnings forecast; shares fall * Lowers top-end of profit outlook to $3.17/share from $3.19 (Corrects name of chain store in second line of second paragraph to TJ Maxx from TJX Maxx.)UPDATE 1-Retailer TJX cuts full-year earnings forecast; shares fall * Lowers top-end of profit outlook to $3.17/share from $3.19   
TRIP,Italy's antitrust watchdog investigates TripAdvisor, booking sites MILAN, May 20 Italy's competition watchdog is looking into TripAdvisor to see if the influential holiday review website takes appropriate measures to avoid publishing fake opinions. 
UTX,UPDATE 1-Pratt & Whitney secures more than 5,500 orders for new engine EAST HARTFORD, Conn., May 20 Pratt & Whitney, a unit of United Technologies Corp, has secured more than 5,500 orders for its closely watched geared turbofan engine for commercial jets, its top executive said on Tuesday. 
WFC,BRIEF-Wells Fargo updates payout targetsWells Fargo is looking to pay out more to investors - CFOON THE MOVE-Disgruntled Wells Fargo team jumps to Raymond JamesBRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.    BRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   NEW YORK, May 20 Robert J. Wood, a financial adviser with Wells Fargo Advisors, said on Tuesday he jumped with two other brokers to Raymond James Financial in Richmond, Va., last Friday because of frustration over pressure to sell Wells Fargo & Co bank products.BRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.     ON THE MOVE-Disgruntled Wells Fargo team jumps to Raymond JamesBRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.    BRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   NEW YORK, May 20 Robert J. Wood, a financial adviser with Wells Fargo Advisors, said on Tuesday he jumped with two other brokers to Raymond James Financial in Richmond, Va., last Friday because of frustration over pressure to sell Wells Fargo & Co bank products.BRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.    May 20 Wells Fargo & Co plans to return as much as 75 percent of its profits to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.ON THE MOVE-Disgruntled Wells Fargo team jumps to Raymond JamesBRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.    BRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   NEW YORK, May 20 Robert J. Wood, a financial adviser with Wells Fargo Advisors, said on Tuesday he jumped with two other brokers to Raymond James Financial in Richmond, Va., last Friday because of frustration over pressure to sell Wells Fargo & Co bank products.BRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.      Wells Fargo is looking to pay out more to investors - CFOON THE MOVE-Disgruntled Wells Fargo team jumps to Raymond JamesBRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.    BRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   NEW YORK, May 20 Robert J. Wood, a financial adviser with Wells Fargo Advisors, said on Tuesday he jumped with two other brokers to Raymond James Financial in Richmond, Va., last Friday because of frustration over pressure to sell Wells Fargo & Co bank products.BRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.     ON THE MOVE-Disgruntled Wells Fargo team jumps to Raymond JamesBRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.    BRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   NEW YORK, May 20 Robert J. Wood, a financial adviser with Wells Fargo Advisors, said on Tuesday he jumped with two other brokers to Raymond James Financial in Richmond, Va., last Friday because of frustration over pressure to sell Wells Fargo & Co bank products.BRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.    May 20 Wells Fargo & Co plans to return as much as 75 percent of its profits to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.ON THE MOVE-Disgruntled Wells Fargo team jumps to Raymond JamesBRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.    BRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   NEW YORK, May 20 Robert J. Wood, a financial adviser with Wells Fargo Advisors, said on Tuesday he jumped with two other brokers to Raymond James Financial in Richmond, Va., last Friday because of frustration over pressure to sell Wells Fargo & Co bank products.BRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.     May 20 Wells Fargo & Co chief financial officer John Shrewsberry said on Tuesday at the bank's investor day:  * Wells Fargo will target a net payout ratio of between 55 and 75 percent  * The bank's net payout ratio in 2013 was 34 percent  * Net payout ratio includes common stock dividends and share repurchases minusWells Fargo is looking to pay out more to investors - CFOON THE MOVE-Disgruntled Wells Fargo team jumps to Raymond JamesBRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.    BRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   NEW YORK, May 20 Robert J. Wood, a financial adviser with Wells Fargo Advisors, said on Tuesday he jumped with two other brokers to Raymond James Financial in Richmond, Va., last Friday because of frustration over pressure to sell Wells Fargo & Co bank products.BRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.     ON THE MOVE-Disgruntled Wells Fargo team jumps to Raymond JamesBRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.    BRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   NEW YORK, May 20 Robert J. Wood, a financial adviser with Wells Fargo Advisors, said on Tuesday he jumped with two other brokers to Raymond James Financial in Richmond, Va., last Friday because of frustration over pressure to sell Wells Fargo & Co bank products.BRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.    May 20 Wells Fargo & Co plans to return as much as 75 percent of its profits to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.ON THE MOVE-Disgruntled Wells Fargo team jumps to Raymond JamesBRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.    BRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   NEW YORK, May 20 Robert J. Wood, a financial adviser with Wells Fargo Advisors, said on Tuesday he jumped with two other brokers to Raymond James Financial in Richmond, Va., last Friday because of frustration over pressure to sell Wells Fargo & Co bank products.BRIEF-Wells Fargo mortgage unit to be profitable in '14BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.   BRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  May 20 Wells Fargo & Co Home Loan president Mike Heid said on Tuesday at the bank's investor day:  * Expects mortgage production business to be profitable in 2014, but lower thanBRIEF-Wells Fargo sets higher margin target for wealth unitUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.  UPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday. May 20 Wells Fargo & Co 's Wealth, Brokerage and Retirement executive David Carroll said on Tuesday at the bank's investor day:  * The unit is increasing its target for pretax margin to 25% from 22% previouslyUPDATE 1-Wells Fargo hopes to double payout to investors -CFO May 20 Wells Fargo & Co plans to return as much as 75 percent of its profit to shareholders, up from 34 percent in 2013, a top executive said on Tuesday.      
